Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada

• DOI: 10.1186/s12879-015-0969-x
• Publication Date: 2015-07-16T11:17:36Z
• Authors: Sophie Patterson; Angela Cescon; Hasina Samji; Keith Chan; Wendy Zhang; Janet Raboud; Ann N. Burchell; Curtis Cooper; Marina B. Klein; Sean B. Rourke; Mona R. Loutfy; Nima Machouf; Julio S. G. Montaner; Chris Tsoukas; Robert S. Hogg
• Keywords: Medical microbiology; Parasitology; Tropical Medicine

We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination antiretroviral therapy (ART) across Canada, consider the potential error introduced by participant loss follow-up (LTFU).Our study used data from Canadian Observational Cohort (CANOC) collaboration, including aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates eight sites in British Columbia, Ontario, Quebec. computed abridged life-tables remaining expectancies at age 20 compared outcomes calendar period patient characteristics treatment initiation. To correct for underreporting due LTFU, we conservatively estimated 30% among participants lost follow-up.9997 contributed 49,589 person-years 830 deaths a crude rate 16.7 [standard (SE) 0.6] per 1000 person-years. When assigning death follow-up, 1170 23.6 [SE 0.7] overall was 45.2 37.5 adjusting LTFU. In LTFU-adjusted analysis, lower observed women men (32.4 1.1] vs. 39.2 years), with injection drug use (IDU) history those without IDU (23.9 1.0] 52.3 0.8] reporting Aboriginal ancestry no (17.7 1.5] 51.2 CD4 count <350 cells/μL ≥350 initiation (36.3 43.5 1.3] years). Life 2000-2003 than periods 2004-2007 2008-2012 analyses (30.8 0.9] 38.6 54.2 1.4]).Life receiving differ Failure LTFU may result underestimation rates overestimation expectancy.